Mozavaptan
Mozavaptan Basic information
- Product Name:
- Mozavaptan
- Synonyms:
-
- OPC 31260
- MOZAVAPTAN
- 5-(Dimethylamino)-1-[4-(2-methylbenzamido)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine
- Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-
- -2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)
- N-(4-(5-(Dimethylamino)
- CS-134
- OPC-31260; OPC31260L; OPC 31260
- CAS:
- 137975-06-5
- MF:
- C27H29N3O2
- MW:
- 427.54
- EINECS:
- 1312995-182-4
- Product Categories:
-
- Inhibitors
- Pharmaceutical intermediate
- Mol File:
- 137975-06-5.mol
Mozavaptan Chemical Properties
- Melting point:
- 213 - 217°C
- Boiling point:
- 543.0±50.0 °C(Predicted)
- Density
- 1.21±0.1 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- form
- Solid
- pka
- 13.04±0.70(Predicted)
- color
- White to Off-White
Mozavaptan Usage And Synthesis
Description
Mozavaptan is an oral vasopressin V2 antagonist that has been launched in Japan for inappropriate antidiuretic hormone secretion syndrome (IADHS), an affliction manifesting as hyponatremia. It joins another nonpeptidic benzazepine, conivaptan, which corrects sodium and water imbalance by blocking the renal V2 receptor resulting in enhanced diuresis, thereby effectively increasing serum sodium concentration. While conivaptan inhibits both V1 and V2 receptors, mozavaptan is significantly more selective for V2 (IC50 of 14nM vs. 1.2 mM for V1).
Originator
Otsuka (Japan)
Uses
Mozavaptan is a vasopressin-receptor antagonist. It is used in the treatment of congestive heart failure and hyponatremia.
Uses
vasopressin V2 receptor antagonist
Definition
ChEBI: Mozavaptan is a member of benzamides.
brand name
Physuline
Synthesis
The reported synthesis of mozavaptan is shown in the scheme. Readily available benzazepin-5-one 39 was refluxed with 40% methyl amine methanol solution in the presence of molecular sieves for 5h followed by the reduction of the resulting imine with sodium borohydride to give the monomethyl amine. Reductive alkylation of the monomethyl amine with formaldehyde in the presence of sodium cyanoborohydride gave the dimethyl amino benzazepine 40. Removal of the tosyl group was facilitated by heating 40 in polyphosphoric acid at 150oC for 2 h to give 41 in 97% yield. Reaction of the resulting benzazepine 41 with p-nitrobenzoyl chloride (42) in the presence of triethylamine provided amide 43 which was hydrogenated in the presence of 10% Pd/C in ethanol at room temperature to give aniline 44. Acylation of aniline 44 with 2-methylbenzoylchloride (45) in the presence of triethylamine gave mozavaptan (VI) in 54% yield.
MozavaptanSupplier
- Tel
- 021-61350663 13052117465
- sales@zehanbiopharma.com
- Tel
- 793-5181188 18170363299
- yangyuening@jxjfpharma.com
- Tel
- 0519-85788828 13775037613
- sales@chemrenpharm.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 13817811078
- sales@jingyan-chemical.com
Mozavaptan(137975-06-5)Related Product Information
- Pyrazine
- (S)-(+)-Benzyl glycidyl ether
- Iodobenzene
- N-ACETYL-L-TYROSINE ETHYL ESTER
- β-Lonone
- 3-Hydroxypyridine
- Pyrrolidine
- Indoline
- Isoquinoline
- Tolvaptan
- Pidotimod
- Mozavaptan
- 2,3,4,5-Tetrahydro-1H-benzo[b]azepine
- 2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPIN-5-YLAMINE
- N-{4-[(methylamino)methyl]phenyl}acetamide
- 4-amino-N-(2-ethylphenyl)benzamide
- 4-AMINO-N-ETHYL-N-PHENYLBENZAMIDE
- Mozavaptan Hydrochloride